The potential revenue stream from Rynocil just for kids is extraordinary and I'm happy with discounts for poor kids. US$1.552m for a treatment is way out of reach for the families without insurance.
Hopefully revenue will help development of the next line of exciting drugs - Rynocil for > 18YO, IBD, Crohn's, CLBP (huge market), heart stuff, etc. And that does not take into consideration other uses for the tech. If they can get 50% of these over the line in the next year or 2 MSB could be seen in retrospect as a bargain at $2.
MSB is and alway was a long term investment where patience and big cahoonas should be rewarded.
(20min delay)